Modeling of human factor Va inactivation by activated protein C

BMC Systems Biology

Stephen J Everse²  Kenneth G Mann³  Thomas Orfeo³  Maria Cristina Bravo¹ 

[1]Cell and Molecular Biology Program, University of Vermont, 89 Beaumont Ave, Burlington, VT 05405, USA

[2]Department of Biochemistry, University of Vermont, 89 Beaumont Ave., Given B418, Burlington, VT 05405, USA

[3]Department of Biochemistry, University of Vermont, 208 South Park Drive, Colchester, VT 05446, USA

关键词: Mathematical modeling;    Factor Xa;    Prothrombin;    Prothrombinase;    Activated protein C;    Factor Va;    Coagulation;   

Others  :  1144475
DOI  :  10.1186/1752-0509-6-45

 received in 2012-02-15, accepted in 2012-05-20,  发布年份 2012

【 摘 要 】

Background

Because understanding of the inventory, connectivity and dynamics of the components characterizing the process of coagulation is relatively mature, it has become an attractive target for physiochemical modeling. Such models can potentially improve the design of therapeutics. The prothrombinase complex (composed of the protease factor (F)Xa and its cofactor FVa) plays a central role in this network as the main producer of thrombin, which catalyses both the activation of platelets and the conversion of fibrinogen to fibrin, the main substances of a clot. A key negative feedback loop that prevents clot propagation beyond the site of injury is the thrombin-dependent generation of activated protein C (APC), an enzyme that inactivates FVa, thus neutralizing the prothrombinase complex. APC inactivation of FVa is complex, involving the production of partially active intermediates and “protection” of FVa from APC by both FXa and prothrombin. An empirically validated mathematical model of this process would be useful in advancing the predictive capacity of comprehensive models of coagulation.

Results

A model of human APC inactivation of prothrombinase was constructed in a stepwise fashion by analyzing time courses of FVa inactivation in empirical reaction systems with increasing number of interacting components and generating corresponding model constructs of each reaction system. Reaction mechanisms, rate constants and equilibrium constants informing these model constructs were initially derived from various research groups reporting on APC inactivation of FVa in isolation, or in the presence of FXa or prothrombin. Model predictions were assessed against empirical data measuring the appearance and disappearance of multiple FVa degradation intermediates as well as prothrombinase activity changes, with plasma proteins derived from multiple preparations. Our work integrates previously published findings and through the cooperative analysis of in vitro experiments and mathematical constructs we are able to produce a final validated model that includes 24 chemical reactions and interactions with 14 unique rate constants which describe the flux in concentrations of 24 species.

Conclusion

This study highlights the complexity of the inactivation process and provides a module of equations describing the Protein C pathway that can be integrated into existing comprehensive mathematical models describing tissue factor initiated coagulation.

【 授权许可】

   
2012 Bravo et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

Figure 10.

【 参考文献 】

• [1]Esmon CT, Suttie JW, Jackson CM: The functional significance of vitamin K action. Difference in phospholipid binding between normal and abnormal prothrombin. J Biol Chem 1975, 250:4095-4099.
• [2]Nesheim ME, Taswell JB, Mann KG: The contribution of bovine Factor V and Factor Va to the activity of prothrombinase. J Biol Chem 1979, 254:10952-10962.
• [3]Rosing J, Tans G, Govers-Riemslag JW, Zwaal RF, Hemker HC: The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 1980, 255:274-283.
• [4]Esmon CT: The subunit structure of thrombin-activated factor V. Isolation of activated factor V, separation of subunits, and reconstitution of biological activity. J Biol Chem 1979, 254:964-973.
• [5]Nesheim ME, Myrmel KH, Hibbard L, Mann KG: Isolation and characterization of single chain bovine factor V. J Biol Chem 1979, 254:508-517.
• [6]Laki K, Gladner JA: Chemistry and Physiology of the Fibrinogen-Fibrin Transition. Physiol Rev 1964, 44:127-160.
• [7]Doolittle RF: Structural aspects of the fibrinogen to fibrin conversion. Adv Protein Chem 1973, 27:1-109.
• [8]Lorand L, Downey J, Gotoh T, Jacobsen A, Tokura S: The transpeptidase system which crosslinks fibrin by gamma-glutamyle-episilon-lysine bonds. Biochem Biophys Res Commun 1968, 31:222-230.
• [9]Doolittle RF, Chen R, Lau F: Hybrid fibrin: proof of the intermolecular nature of - crosslinking units. Biochem Biophys Res Commun 1971, 44:94-100.
• [10]Rezaie AR: Determinants of specificity of factor xa interaction with its physiological inhibitors. Mini Rev Med Chem 2006, 6:859-865.
• [11]Ellis V, Scully M, MacGregor I, Kakkar V: Inhibition of human factor Xa by various plasma protease inhibitors. Biochim Biophys Acta 1982, 701:24-31.
• [12]Kisiel W, Canfield WM, Ericsson LH, Davie EW: Anticoagulant properties of bovine plasma protein C following activation by thrombin. Biochemistry 1977, 16:5824-5831.
• [13]Fay PJ, Smudzin TM, Walker FJ: Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity. J Biol Chem 1991, 266:20139-20145.
• [14]Walker FJ: Regulation of activated protein C by protein S. The role of phospholipid in factor Va inactivation. J Biol Chem 1981, 256:11128-11131.
• [15]Kalafatis M, Rand MD, Mann KG: The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994, 269:31869-31880.
• [16]Esmon CT: The protein C pathway. Chest 2003, 124:26S-32S.
• [17]Castoldi E, Hackeng TM: Regulation of coagulation by protein S. Curr Opin Hematol 2008, 15:529-536.
• [18]Meijers JC, Herwald H: Protein C inhibitor. Semin Thromb Hemost 2011, 37:349-354.
• [19]Rezaie AR, Cooper ST, Church FC, Esmon CT: Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex. J Biol Chem 1995, 270:25336-25339.
• [20]Esmon CT: Basic mechanisms and pathogenesis of venous thrombosis. Blood Rev 2009, 23:225-229.
• [21]Dahlback B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993, 90:1004-1008.
• [22]Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994, 369:64-67.
• [23]Krishnaswamy S, Williams EB, Mann KG: The binding of activated protein C to factors V and Va. J Biol Chem 1986, 261:9684-9693.
• [24]Yu S, Zhang L, Jhingan A, Christiansen WT, Castellino FJ: Construction, expression, and properties of a recombinant chimeric human protein C with replacement of its growth factor-like domains by those of human coagulation factor IX. Biochemistry 1994, 33:823-831.
• [25]Mesters RM, Heeb MJ, Griffin JH: A novel exosite in the light chain of human activated protein C essential for interaction with blood coagulation factor Va. Biochemistry 1993, 32:12656-12663.
• [26]Segers K, Dahlback B, Rosing J, Nicolaes GA: Identification of surface epitopes of human coagulation factor Va that are important for interaction with activated protein C and heparin. J Biol Chem 2008, 283:22573-22581.
• [27]Yegneswaran S, Kojima Y, Nguyen PM, Gale AJ, Heeb MJ, Griffin JH: Factor Va residues 311–325 represent an activated protein C binding region. J Biol Chem 2007, 282:28353-28361.
• [28]Nicolaes GA, Bock PE, Segers K, Wildhagen KC, Dahlback B, Rosing J: Inhibition of thrombin formation by active site mutated (S360A) activated protein C. J Biol Chem 2010, 285:22890-22900.
• [29]Kalafatis M, Bertina RM, Rand MD, Mann KG: Characterization of the molecular defect in factor VR506Q. J Biol Chem 1995, 270:4053-4057.
• [30]Kalafatis M, Mann KG: Role of the membrane in the inactivation of factor Va by activated protein C. J Biol Chem 1993, 268:27246-27257.
• [31]Nicolaes GA, Tans G, Thomassen MC, Hemker HC, Pabinger I, Varadi K, Schwarz HP, Rosing J: Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995, 270:21158-21166.
• [32]Mann KG, Hockin MF, Begin KJ, Kalafatis M: Activated protein C cleavage of factor Va leads to dissociation of the A2 domain. J Biol Chem 1997, 272:20678-20683.
• [33]Hockin MF, Cawthern KM, Kalafatis M, Mann KG: A model describing the inactivation of factor Va by APC: bond cleavage, fragment dissociation, and product inhibition. Biochemistry 1999, 38:6918-6934.
• [34]Kim PY, Nesheim ME: Down regulation of prothrombinase by activated protein C during prothrombin activation. Thromb Haemost 2010, 104:61-70.
• [35]Nesheim ME, Canfield WM, Kisiel W, Mann KG: Studies of the capacity of factor Xa to protect factor Va from inactivation by activated protein C. J Biol Chem 1982, 257:1443-1447.
• [36]Norstrom EA, Tran S, Steen M, Dahlback B: Effects of factor Xa and protein S on the individual activated protein C-mediated cleavages of coagulation factor Va. J Biol Chem 2006, 281:31486-31494.
• [37]Rosing J, Hoekema L, Nicolaes GA, Thomassen MC, Hemker HC, Varadi K, Schwarz HP, Tans G: Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995, 270:27852-27858.
• [38]Suzuki K, Stenflo J, Dahlback B, Teodorsson B: Inactivation of human coagulation factor V by activated protein C. J Biol Chem 1983, 258:1914-1920.
• [39]Tran S, Norstrom E, Dahlback B: Effects of prothrombin on the individual activated protein C-mediated cleavages of coagulation factor Va. J Biol Chem 2008, 283:6648-6655.
• [40]Yegneswaran S, Nguyen PM, Gale AJ, Griffin JH: Prothrombin amino terminal region helps protect coagulation factor Va from proteolytic inactivation by activated protein C. Thromb Haemost 2009, 101:55-61.
• [41]Egan JO, Kalafatis M, Mann KG: The effect of Arg306– > Ala and Arg506– > Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S. Protein Sci 1997, 6:2016-2027.
• [42]Nicolaes GA, Sorensen KW, Friedrich U, Tans G, Rosing J, Autin L, Dahlback B, Villoutreix BO: Altered inactivation pathway of factor Va by activated protein C in the presence of heparin. Eur J Biochem 2004, 271:2724-2736.
• [43]Danforth CM, Orfeo T, Mann KG, Brummel-Ziedins KE, Everse SJ: The impact of uncertainty in a blood coagulation model. Math Med Biol 2009, 26:323-336.
• [44]Walker FJ, Sexton PW, Esmon CT: The inhibition of blood coagulation by activated Protein C through the selective inactivation of activated Factor V. Biochim Biophys Acta 1979, 571:333-342.
• [45]Nesheim ME, Eid S, Mann KG: Assembly of the prothrombinase complex in the absence of prothrombin. J Biol Chem 1981, 256:9874-9882.
• [46]Jones KC, Mann KG: A model for the tissue factor pathway to thrombin. II. A mathematical simulation. J Biol Chem 1994, 269:23367-23373.
• [47]Hockin MF, Jones KC, Everse SJ, Mann KG: A model for the stoichiometric regulation of blood coagulation. J Biol Chem 2002, 277:18322-18333.
• [48]Krishnaswamy S, Jones KC, Mann KG: Prothrombinase complex assembly. Kinetic mechanism of enzyme assembly on phospholipid vesicles. J Biol Chem 1988, 263:3823-3834.
• [49]Campbell JE, Brummel-Ziedins KE, Butenas S, Mann KG: Cellular regulation of blood coagulation: a model for venous stasis. Blood 2010, 116:6082-6091.
• [50]Odegaard B, Mann K: Proteolysis of factor Va by factor Xa and activated protein C. J Biol Chem 1987, 262:11233-11238.
• [51]Barhoover MA, Kalafatis M: Cleavage at both Arg306 and Arg506 is required and sufficient for timely and efficient inactivation of factor Va by activated protein C. Blood Coagul Fibrinolysis 2011, 22:317-324.
• [52]Everse SJ, Adams TE, Mann KG: A molecular model of the human prothrombinase complex. In Recent Advances in Thrombosis and Hemostasis. Volume 21. Edited by Tanaka K, Davie EW. Springer, Tokyo; 2008:107-132.
• [53]Autin L, Steen M, Dahlback B, Villoutreix BO: Proposed structural models of the prothrombinase (FXa-FVa) complex. Proteins 2006, 63:440-450.
• [54]Lee CJ, Lin P, Chandrasekaran V, Duke RE, Everse SJ, Perera L, Pedersen LG: Proposed structural models of human factor Va and prothrombinase. J Thromb Haemost 2008, 6:83-89.
• [55]Kamata K, Kawamoto H, Honma T, Iwama T, Kim SH: Structural basis for chemical inhibition of human blood coagulation factor Xa. Proc Natl Acad Sci U S A 1998, 95:6630-6635.
• [56]Adams TE, Hockin MF, Mann KG, Everse SJ: The crystal structure of activated protein C-inactivated bovine factor Va: Implications for cofactor function. Proc Natl Acad Sci U S A 2004, 101:8918-8923.
• [57]Zaitseva I, Zaitsev V, Card G, Moshkov K, Bax B, Ralph A, Lindley P: The X-ray structure of human serum ceruloplasmin at 3.1 angstrom: Nature of the copper centres. J Biol Inorg Chem 1996, 1:15-23.
• [58]Guinto ER, Esmon CT: Loss of prothrombin and of factor Xa-factor Va interactions upon inactivation of factor Va by activated protein C. J Biol Chem 1984, 259:13986-13992.
• [59]Shaw AW, Pureza VS, Sligar SG, Morrissey JH: The local phospholipid environment modulates the activation of blood clotting. J Biol Chem 2007, 282:6556-6563.
• [60]Higgins DL, Mann KG: The interaction of bovine factor V and factor V-derived peptides with phospholipid vesicles. J Biol Chem 1983, 258:6503-6508.
• [61]Bloom JW, Nesheim ME, Mann KG: Phospholipid-binding properties of bovine factor V and factor Va. Biochemistry 1979, 18:4419-4425.
• [62]Lu Y, Nelsestuen GL: Dynamic features of prothrombin interaction with phospholipid vesicles of different size and composition: implications for protein–membrane contact. Biochemistry 1996, 35:8193-8200.
• [63]Krishnaswamy S, Mann KG: The binding of factor Va to phospholipid vesicles. J Biol Chem 1988, 263:5714-5723.
• [64]Smirnov MD, Safa O, Regan L, Mather T, Stearns-Kurosawa DJ, Kurosawa S, Rezaie AR, Esmon NL, Esmon CT: A chimeric protein C containing the prothrombin Gla domain exhibits increased anticoagulant activity and altered phospholipid specificity. J Biol Chem 1998, 273:9031-9040.
• [65]Morrissey JH, Pureza V, Davis-Harrison RL, Sligar SG, Rienstra CM, Kijac AZ, Ohkubo YZ, Tajkhorshid E: Protein-membrane interactions: blood clotting on nanoscale bilayers. J Thromb Haemost 2009, 7(Suppl 1):169-172.
• [66]Bakker HM, Tans G, Janssen-Claessen T, Thomassen MC, Hemker HC, Griffin JH, Rosing J: The effect of phospholipids, calcium ions and protein S on rate constants of human factor Va inactivation by activated human protein C. Eur J Biochem 1992, 208:171-178.
• [67]Smirnov MD, Triplett DT, Comp PC, Esmon NL, Esmon CT: On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 1995, 95:309-316.
• [68]Smirnov MD, Ford DA, Esmon CT, Esmon NL: The effect of membrane composition on the hemostatic balance. Biochemistry 1999, 38:3591-3598.
• [69]Jordan SW, Chaikof EL: Simulated surface-induced thrombin generation in a flow field. Biophys J 2011, 101:276-286.
• [70]Bungay SD, Gentry PA, Gentry RD: A mathematical model of lipid-mediated thrombin generation. Math Med Biol 2003, 20:105-129.
• [71]Qiao YH, Xu CQ, Zeng YJ, Xu XH, Zhao H, Xu H: The kinetic model and simulation of blood coagulation–the kinetic influence of activated protein C. Med Eng Phys 2004, 26:341-347.
• [72]Qiao YH, Liu JL, Zeng YJ: A kinetic model for simulation of blood coagulation and inhibition in the intrinsic path. J Med Eng Technol 2005, 29:70-74.
• [73]Anand M, Rajagopal K, Rajagopal KR: A model for the formation, growth, and lysis of clots in quiescent plasma. A comparison between the effects of antithrombin III deficiency and protein C deficiency. J Theor Biol 2008, 253:725-738.
• [74]Kuharsky AL, Fogelson AL: Surface-mediated control of blood coagulation: the role of binding site densities and platelet deposition. Biophys J 2001, 80:1050-1074.
• [75]Fogelson AL, Tania N: Coagulation under flow: the influence of flow-mediated transport on the initiation and inhibition of coagulation. Pathophysiol Haemost Thromb 2005, 34:91-108.
• [76]Ermakova EA, Panteleev MA, Shnol EE: Blood coagulation and propagation of autowaves in flow. Pathophysiol Haemost Thromb 2005, 34:135-142.
• [77]Kastrup CJ, Shen F, Runyon MK, Ismagilov RF: Characterization of the threshold response of initiation of blood clotting to stimulus patch size. Biophys J 2007, 93:2969-2977.
• [78]Panteleev MA, Ovanesov MV, Kireev DA, Shibeko AM, Sinauridze EI, Ananyeva NM, Butylin AA, Saenko EL, Ataullakhanov FI: Spatial propagation and localization of blood coagulation are regulated by intrinsic and protein C pathways, respectively. Biophys J 2006, 90:1489-1500.
• [79]Luan D, Zai M, Varner JD: Computationally derived points of fragility of a human cascade are consistent with current therapeutic strategies. PLoS Comput Biol 2007, 3:e142.
• [80]Wagenvoord R, Hemker PW, Hemker HC: The limits of simulation of the clotting system. J Thromb Haemost 2006, 4:1331-1338.
• [81]Bajaj SP, Mann KG: Simultaneous purification of bovine prothrombin and factor X. Activation of prothrombin by trypsin-activated factor X. J Biol Chem 1973, 248:7729-7741.
• [82]Krishnaswamy S, Church WR, Nesheim ME, Mann KG: Activation of human prothrombin by human prothrombinase. Influence of factor Va on the reaction mechanism. J Biol Chem 1987, 262:3291-3299.
• [83]Katzmann JA, Nesheim ME, Hibbard LS, Mann KG: Isolation of functional human coagulation factor V by using a hybridoma antibody. Proc Natl Acad Sci U S A 1981, 78:162-166.
• [84]Barenholz Y, Gibbes D, Litman BJ, Goll J, Thompson TE, Carlson RD: A simple method for the preparation of homogeneous phospholipid vesicles. Biochemistry 1977, 16:2806-2810.
• [85]Pryzdial EL, Mann KG: The association of coagulation factor Xa and factor Va. J Biol Chem 1991, 266:8969-8977.